2007 Adverse Analytical Findings * Reported by Accredited Laboratories. Overview of Results. Olympic and Non-Olympic: Adverse Analytical Findings Rate

Transcription

1 Overview of Results Table A Olympic and Non-Olympic: Analytical Findings Rate Differentiation between Olympic and Non-Olympic s A Samples Analyzed A Sample Analytical % Olympic s Non-Olympic s 174,483 3, % 49,415 1, % 223,898 4, % * NOTE: The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). " Analytical Finding " is defined in the World Anti-Doping Code as "a report from a laboratory or other WADA - approved entity that, consistent with the International Standard for Laboratories and related Technical Documents, identifies in a Sample the presence of a Prohibited Substance or its Metabolites or Markers (including elevated quantities of endogenous substances) or evidence of the Use of a Prohibited Method." These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. Page 1 of 13

2 Comparison of years 2003 to 2007 Table A1 Olympic and Non-Olympic Statistics Differentiation between Olympic and Non-Olympic s 2003 A Samples Analyzed 2004 A Samples Analyzed 2005 A Samples Analyzed 2006 A Samples Analyzed 2007 A Samples Analyzed % difference 2007 vs 2006 Olympic s Non-Olympic s 113, , , , , % 37,651 40,596 43,501 41,277 49, % 151, , , , , % Differentiation between Olympic and Non-Olympic s Olympic s Non-Olympic s A Samples A Samples A Samples A Samples A Samples Analytical Analytical Analytical Analytical Analytical % difference 2007 vs ,707 2,145 2,958 2,915 3, % , % 2,447 2,909 3,909 3,887 4, % Differentiation between Olympic and Non-Olympic s Olympic s Non-Olympic s Overall 2003 % % % % % % difference 2007 vs % % % * The Analytical Finding s (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 2 of 13

3 Table B Total Analytical per Laboratory N N Laboratory Total Analytical % 1 Sydney, Australia 7, Seibersdorf, Austria 4, Ghent, Belgium 6, Rio de Janeiro, Brazil 5, Montreal, Canada 15, Beijing, China 10, Bogota, Colombia 2, Havana, Cuba 2, Prague, Czech Republic 1, Helsinki, Finland 2, Paris, France 9, Cologne, Germany 13, Kreischa, Germany 6, London, UK 8, Athens, Greece 5, Rome, Italy 10, Tokyo, Japan 6, Seoul, Korea 2, Penang, Malaysia 3, Oslo, Norway 4, Warsaw, Poland 2, Lisbon, Portugal 3, Bloemfontein, South Africa 2, Moscow, Russia 8, Barcelona, Spain 3, Madrid, Spain 7, Stockholm, Sweden 4, Lausanne, Switzerland 5, Bangkok, Thailand 3, Tunis, Tunisia 1, Ankara, Turkey 3, Los Angeles, USA 38, Salt Lake City, USA 10, ,898 4, % * The Analytical Finding s (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 3 of 13

4 Table B1 Olympic Analytical per Laboratory N N Laboratory Total Analytical % 1 Sydney, Australia 4, Seibersdorf, Austria 4, Ghent, Belgium 5, Rio de Janeiro, Brazil 5, Montreal, Canada 14, Beijing, China 9, Bogota, Colombia 2, Havana, Cuba 2, Prague, Czech Republic 1, Helsinki, Finland 1, Paris, France 7, Cologne, Germany 11, Kreischa, Germany 5, London, UK 6, Athens, Greece 4, Rome, Italy 9, Tokyo, Japan 5, Seoul, Korea 2, Penang, Malaysia 2, Oslo, Norway 3, Warsaw, Poland 2, Lisbon, Portugal 2, Bloemfontein, South Africa 1, Moscow, Russia 8, Barcelona, Spain 2, Madrid, Spain 6, Stockholm, Sweden 3, Lausanne, Switzerland 4, Bangkok, Thailand 2, Tunis, Tunisia 1, Ankara, Turkey 2, Los Angeles, USA 21, Salt Lake City, USA 2, ,483 3, % * The Analytical Finding s (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytica Findings correspond to multiple measurements performed on the same Athlete such as in the case of longitudinal studies on testosterone. Page 4 of 13

5 Table B2 Non-Olympic Analytical per Laboratory N N Laboratory Total Analytical % 1 Sydney, Australia 3, Seibersdorf, Austria Ghent, Belgium 1, Rio de Janeiro, Brazil Montreal, Canada Beijing, China Bogota, Colombia Havana, Cuba Prague, Czech Republic Helsinki, Finland Paris, France 1, Cologne, Germany 1, Kreischa, Germany London, UK 1, Athens, Greece Rome, Italy Tokyo, Japan Seoul, Korea Penang, Malaysia Oslo, Norway Warsaw, Poland Lisbon, Portugal Bloemfontein, South Africa Moscow, Russia Barcelona, Spain Madrid, Spain Stockholm, Sweden Lausanne, Switzerland Bangkok, Thailand 1, Tunis, Tunisia Ankara, Turkey Los Angeles, USA 16, Salt Lake City, USA 7, ,415 1, % * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 5 of 13

6 Table C 2007 Analytical Findings* Reported by Accredited Laboratories Olympic Sample Analysis Discipline Aquatics 3,867 Diving 301 Aquatics Swimming 7,179 12, % Synchronised Swimming 165 Water Polo 1,038 Archery - - 1, % Athletics , % Badminton % Baseball , % Basketball - - 8, % Biathlon - - 1, % Bobsleigh 780 Bobsleigh Tobogganing % Skeleton 40 Boxing - - 2, % Canoe / Kayak - - 3, % Curling % Cycling Cycling 16,209 Mountain Bike , % Equestrian % Fencing - - 2, % Football , % Gymnastics 1,959 Gymnastics Artistic Gymnastics 157 Rhythmic Gymnastics 63 2, % Trampoline 94 Handball - - 3, % Hockey - - 1, % Ice Hockey - - 4, % Judo - - 3, % Luge % Modern Pentathlon % Rowing - - 4, % Sailing - - 1, % Shooting - - 2, % Skating 1,805 Skating Speed Skating 891 3, % Skiing Total per Discipline Figure Skating 400 Skiing 2,414 Alpine Skiing 227 Cross Country Ski 616 Ski Jumping 93 Snowboard 283 Combined Skiing 53 Freestyle Skiing 158 Total per A Sample Analytical 3, % Softball % Table Tennis % Taekwondo - - 1, % Tennis - - 3, % Triathlon - - 2, % Volleyball Volleyball 3,890 Beach Volleyball 246 4, % Weightlifting - - 6, % Wrestling - - 3, % Baseball / Softball % Ice % Total 174,483 3, % 1 "Baseball/Softball" and "Ice " were designated on Doping Control Forms and unable to assign by single sport or federation. % * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 6 of 13

7 Table D1 Sample Analysis in Selected** IOC Recognized s Discipline Roller Hockey 15 Rollersports Roller Skating % Roller s 327 Golf % Karate % Rugby , % Squash % Total per Discipline ** as requested by the International Olympic Committee. 1 Includes Samples noted as "Rugby" and "Rugby Union". Total per Analytical % adverse 6, % Table D2 Sample Analysis in Other IOC Recognized s Air s Bandy Billiard s Boules Bowling Bridge Chess Dance Korfball Life Saving Motorcycle Racing Mountaineering and Climbing Netball Orienteering Pelote Basque Polo Powerboating Racquetball Sumo Surfing Tug of War Underwater s Water Skiing Wushu Total per Analytical % % % % % % % % % % % % % % % % % % % % % % % % % 4, % Table E Sample Analysis in Paralympic s Paralympic s Total per Analytical % 1, % * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 7 of 13

8 Table F Number of Substances Identified in Each Drug Class Substance Group Number* % of all Analytical Findings S1. Anabolic Agents 2, % S6. Stimulants % S8. Cannabinoids % S3. Beta-2 Agonists % S5. Diuretics and Other Masking Agents % S9. Glucocorticosteroids % S2. Hormones and Related Substances % P2. Beta-Blockers % S7. Narcotics % S4. Agents with Anti-Estrogenic Activity % M1. Enhancement of Oxygen Transfer 3 0.1% M2. Chemical and Physical Manipulation 3 0.1% 4,850 * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti- Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 8 of 13

9 Table G Substances Identified in Each Drug Class S1.1.a. Anabolic Agents - Exogenous AAS Occurences Nandrolone % Stanozolol % Methandienone % Boldenone % Methyltestosterone % Metenolone % Drostanolone % Oxandrolone % Mesterolone % Trenbolone % Dehydrochlormethyltestosterone 7 0.3% Mestanolone 7 0.3% Oxymetholone 4 0.2% Methasterone 3 0.1% Clostebol 2 0.1% Danazol 2 0.1% Fluoxymesterone 1 0.0% Prostanozol 1 0.0% subtotal* 646 S1.1.b. Anabolic Agents - Endogenous AAS 1 Occurences Testosterone 1, % Prasterone (DHEA) 7 0.3% 6α-OH-Androstendione 3 0.1% Etiocholanolone 2 0.1% Androsterone 2 0.1% Testosterone precursors 1 0.0% 5-androstendione 1 0.0% subtotal* 1,623 S.1.2 Other Anabolic Agents Occurences Clenbuterol % subtotal* 53 S.1. All Anabolic Agents * Occurences 2,322 1 Reporting of an Endogenous AAS may be due to detection of a concentration outside normal reference ranges and/or establishment of an exogenous source by GC/C/IRMS. S2. Hormones and Related Substances Occurences Erythropoetin (EPO) % Gonadotrophins (hcg) % Gonadotrophins (LH) 2 4.9% Erythropoetin (Darbepoetin) 2 4.9% * 41 * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 9 of 13

10 Table G (cont'd) Substances Identified in Each Drug Class S3. Beta-2 Agonists Occurences Terbutaline % Formoterol % Salbutamol % Salmeterol % Fenoterol % Reproterol 2 0.5% * 399 S4. Agents with anti-estrogenic activity Occurences Tamoxifen % Clomiphene % Formestane % 6alpha-methylandrostendione % Androst-1,4,6-triene-3,17-dione (ATD) % Letrozole 1 5.6% * 18 S5. Diuretics and other masking agents Occurences Furosemide % Hydrochlorothiazide % Finasteride % Canrenone % Triamterene % Epitestosterone % Amiloride % Bumetanide 7 1.9% Chlorothiazide 7 1.9% Chlortalidone 6 1.7% Indapamide 4 1.1% Acetazolamide 4 1.1% Bendroflumethazide 3 0.8% Probenecid 3 0.8% Althiazide 2 0.6% Spironolactone 1 0.3% Trimethylchlorothiazide 1 0.3% * 359 * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 10 of 13

11 Table G (cont'd) Substances Identified in Each Drug Class S6. Stimulants Occurences Amphetamine % Cocaine % Ephedrine % Methylphenidate % Cathine % Methamphetamine % Sibutramine % Clobenzorex % Modafinil % Heptaminol % Phentermine 9 1.1% 4-phenylpiracetam (carphedon) 6 0.8% Nikethamide 6 0.8% Isometheptene 6 0.8% Etilefrine 5 0.6% Methylephedrine 4 0.5% Fenetylline 3 0.4% Fenproporex 3 0.4% Octopamine 3 0.4% Strychnine 2 0.3% Tuaminoheptane 2 0.3% Pholedrine 2 0.3% Methylenedioxymethamphetamine 1 0.1% Norfenfluramine 1 0.1% Mephentermine 1 0.1% Phendimetrazine 1 0.1% Phenmetrazine 1 0.1% Benzylpiperazine 1 0.1% * 793 S7. Narcotics Occurences Morphine % Methadone 1 4.8% Hydromorphone 1 4.8% * 21 * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 11 of 13

12 Table G (cont'd) Substances Identified in Each Drug Class S8. Cannabinoids Occurences Cannabinoids % * 576 S9. Glucocorticosteroids Occurences Budesonide % Betamethasone % Prednisolone % Prednisone 7 2.4% Triamcinolone Acetonide % Prednisolone + Prednisone % Methylprednisolone % Dexamethasone 6 2.1% * 288 P2. Beta Blockers Occurences Propanolol % Metoprolol % Bisoprolol % Atenolol % Carvedilol 2 7.4% Carteolol 1 3.7% Timolol 1 3.7% * 27 M1. Enhancement of Oxygen Transfer Occurences Blood Transfusion % * 3 M2. Chemical and Physical Manipulation Occurences Manipulation % * 3 * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 12 of 13

13 Laboratory Table H Total Laboratory Analytical vs Drug Class S1. S2. S3. S4. S5. S6. S7. S8. S9. P2. M1. M2. Anabolic Agents 2007 Analytical Reported by Accredited Laboratories Hormones and Related Substances Beta-2 Agonists Agents with Anti- Estrogenic Activity Diuretics and Other Masking Agents Stimulants Narcotics Cannabinoids Enhancement of Oxygen Transfer Chemical and Physical Manipulation Sydney, Australia % Seibersdorf, Austria % Ghent, Belgium % Rio de Janeiro, Brazil % Montreal, Canada % Beijing, China % Bogota, Colombia % Havana, Cuba % Prague, Czech Republic % Helsinki, Finland % Paris, France % Cologne, Germany % Kreischa, Germany % London, UK % Athens, Greece % Rome, Italy % Tokyo, Japan % Seoul, Korea % Penang, Malaysia % Oslo, Norway % Warsaw, Poland % Lisbon, Portugal % Bloemfontein, S Africa % Moscow, Russia % Barcelona, Spain % Madrid, Spain % Stockholm, Sweden % Lausanne, Switzerland % Bangkok, Thailand % Tunis, Tunisia % Ankara, Turkey % Los Angeles, USA % Salt Lake City, USA % PER DRUG CLASS 2, ,850 % of Drug Class 47.9% 0.8% 8.2% 0.4% 7.4% 16.4% 0.4% 11.9% 5.9% 0.6% 0.1% 0.1% Glucocorticosteroids Beta- Blockers Total per Lab % of total Analytical Findings * The Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Analytical Finding s correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Page 13 of 13